Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Recommendation of “Hold” by Brokerages

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have earned an average rating of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $56.40.

A number of research analysts have weighed in on PSTV shares. Wall Street Zen raised shares of Plus Therapeutics to a “sell” rating in a research report on Saturday, April 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Tuesday, April 21st. D. Boral Capital reissued a “hold” rating on shares of Plus Therapeutics in a research report on Tuesday, March 31st. Finally, Ascendiant Capital Markets reduced their target price on shares of Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research report on Monday, June 8th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PSTV. Jane Street Group LLC acquired a new position in shares of Plus Therapeutics during the second quarter worth $41,000. Scientech Research LLC acquired a new position in shares of Plus Therapeutics during the third quarter worth $100,000. Susquehanna International Group LLP acquired a new position in shares of Plus Therapeutics during the third quarter worth $46,000. Geode Capital Management LLC lifted its position in shares of Plus Therapeutics by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after purchasing an additional 589,544 shares in the last quarter. Finally, L1 Global Manager Pty Ltd acquired a new position in shares of Plus Therapeutics during the fourth quarter worth $1,167,000. 3.28% of the stock is owned by institutional investors and hedge funds.

Plus Therapeutics Stock Down 7.6%

Shares of PSTV stock opened at $5.01 on Friday. The stock has a market cap of $34.47 million, a price-to-earnings ratio of -2.18 and a beta of 1.38. Plus Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $23.42. The firm’s 50 day moving average price is $5.70 and its two-hundred day moving average price is $8.38.

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earnings results on Friday, May 15th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). The business had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.97 million. Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. On average, equities analysts forecast that Plus Therapeutics will post -3.76 EPS for the current fiscal year.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.